Making Precision Decisions in High-Risk HR+, HER2- Metastatic Breast Cancer

Decision-making in metastatic HER2+ breast cancerПодробнее

AC versus TaxAC in High-Risk HER2-Negative MBCПодробнее

Living long term with MBC: Making treatment decisionsПодробнее

Breast Cancer,Risk Factors,Symptoms & Types of Breast CancerПодробнее

Guiding Multifactorial Clinical Decisions in HR+, HER2- Breast CancerПодробнее

Treatment decision making in first line metastatic ER+/Her2- BCПодробнее

Adjuvant CDK4 and 6 Inhibition to Prevent Recurrences in High-Risk HR+/HER2- Early Breast CancerПодробнее

Raising the Bar in HR+/HER2- Early Breast Cancer: CDK4 and 6 InhibitorsПодробнее

Optimisation of Treatment Selection & Sequencing Decisions in ER+/HER2- Breast CancerПодробнее

Managing Recurrent Metastatic ER+/HER2- Breast CancerПодробнее

Factors Influencing Adjuvant Therapy Use for HER2+ Breast CancerПодробнее

Guiding Multifactorial Clinical Decisions in HR+, HER2- Breast CancerПодробнее

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Kaklamani and Dr. O’ReganПодробнее

Key challenge associated with the management of HR+/HER2- breast cancerПодробнее

Personalizing Treatment Decisions in HER2-Altered Breast CancerПодробнее

Treating metastatic breast cancer: The promise of precision medicineПодробнее

monarchE: adjuvant abemaciclib + endocrine therapy in patients with HR+, HER2- high-risk eBCПодробнее

New horizons in high-risk HR+ HER2- EBC: Risk stratification for early identificationПодробнее

Focusing Decision-Making & Communication Strategies to Reduce Recurrence in High-Risk HR+, HER2- EBCПодробнее